All Clinical Trials in United Kingdom

A listing of 3097 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

United Kingdom

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Improving Cognitive Recovery in Multiple Sclerosis

NCT06877273

Recruiting

This study aims to find out whether an adapted version of an existing cognitive rehabilitation program, CIRCuiTS (https://www.circuitstherapyinfo.com), can be used to improve everyday thinking skills for people with Multiple Sclerosis (MS). People living with MS have worked with the study's researchers to adapt CIRCuiTS to meet their needs. They shared the thinking challenges they experience and suggested changes to the program's content and how it is delivered. This study will test whether this... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: King's College London, London, East of England

Conditions: Multiple Sclerosis

Learn More ›

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

NCT06150157

Recruiting

The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: City of Hope, Duarte, California +21 locations

Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis

Learn More ›

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

NCT06852222

Recruiting

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York +33 locations

Roswell Park Comprehensive Cancer Center, Buffalo, New York

Gabrail Cancer Center, Canton, Ohio

Providence Portland Medical Center, Portland, Oregon

Thomas Jefferson University, Philadelphia, Pennsylvania

University of Tennessee, Knoxville, Tennessee

Baylor University Medical Center, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Flinders Medical Centre, Bedford Park, Not set

Royal Prince Alfred Hospital, Camperdown, Not set

St George Hospital, Kogarah, Not set

Peter MacCallum Cancer Centre, Melbourne, Not set

Princess Margaret Cancer Centre University Health Network, Toronto, Ontario

Peking University People s Hospital, Beijing, Not set

Carmel Medical Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah University Hospita Ein Kerem, Jerusalem, Not set

Rabin Medical Center, Petah Tikva, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv Yafo, Not set

Fukushima Medical University Hospital, Fukushima, Not set

Kobe City Medical Center General Hospital, Kobe, Not set

National Hospital Organization Kumamoto Medical Center, Kumamoto shi, Not set

Japanese Red Cross Osaka Hospital, Osaka, Not set

Aiiku Hospital, Sapporo, Not set

Yamagata University Hospital, Yamagata, Not set

University of Fukui Hospital, Yoshida, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

Chi Mei Medical Center Liouying Branch, Tainan, Not set

National Taiwan University Hospital, Taipei City, Not set

Linkou Chang Gung Memorial Hospital, Taoyuan, Not set

Ankara University School of Medicine Cebeci Hospital, Ankara, Not set

Memorial Antalya Hospital, Antalya, Not set

Koc University Medical Faculty, Istanbul, Not set

Ondokuz Mayis University, Samsun, Not set

Derriford Hospital, Plymouth, Not set

Conditions: Leukemia, Myeloid, Acute

Learn More ›

Vibration Exercise for Crohn's to Observe Response

NCT06211400

Recruiting

Background: Crohn's disease (CD) is a long-term inflammatory condition of the digestive system. People with CD often have unpredictable and debilitating symptoms, including abdominal pain, diarrhoea and fatigue. In addition, they require long-term treatment with frequent negative effects and often need surgery and hospitalisations. Therefore, people with CD report a lower health-related quality of life (HRQOL) compared with other people. Doctors are constantly trying to find new treatments to im... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/17/2025

Locations: University of Hertfordshire, Hatfield, UK

Conditions: Crohn's Disease

Learn More ›

Sex Hormones as Regulators of the Age- and Sex-dependent Benefits of Caloric Restriction

NCT07065643

Recruiting

Obesity increases the risk of type 2 diabetes, cardiovascular disease, and certain cancers, primarily due to elevated abdominal fat storage. With nearly two-thirds of the UK population living with overweight or obesity, there is an urgent necessity for evidence-based public health guidance to promote healthy weight. Calorie deficit can facilitate weight loss and body fat reduction, leading to health benefits, such as improved blood glucose control. Current weight management advice centres on lif... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

07/17/2025

Locations: Rowett Institute, University of Aberdeen, Aberdeen, Not set

Conditions: Overweight and Obese Adults, Healthy

Learn More ›

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

NCT06618001

Recruiting

The purpose of Part 1 (Dose Escalation) of the study is to assess the safety and tolerability, and to identify the recommended Phase 2 dose\[s\] (RP2D\[s\]) in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML) (that is a type of blood cancer that has come back after treatment/or has stopped responding to treatment) or R/R higher-risk type of myelodysplastic neoplasms (MDS, type of blood cancer). The purpose of Part 2 (Cohort Expansion) is to further assess the safety, t... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Vancouver General Hospital, Vancouver, British Columbia +6 locations

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Neoplasms

Learn More ›

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

NCT06934226

Recruiting

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

Gender:

ALL

Ages:

12 years and above

Trial Updated:

07/17/2025

Locations: Cahaba Research Inc, Birmingham, Alabama +159 locations

Cahaba Research Inc, Birmingham, Alabama

California Dermatology & Clinical Research Institute, Encinitas, California

T Joseph Raoof Md Inc, Encino, California

First OC Dermatology, Fountain Valley, California

Dermatologist Medical Group of North County, Inc., Oceanside, California

NorCal Clinical Research, Rocklin, California

Integrative Skin Science and Research, Sacramento, California

MedDerm Associates, San Diego, California

Southern California Dermatology, Santa Ana, California

Olive View-UCLA Education & Research Institute, Sylmar, California

University of Conn Health Center, Farmington, Connecticut

Driven Research LLC, Coral Gables, Florida

Bioclinical Research Alliance Inc., Miami, Florida

Renstar Medical Research, Ocala, Florida

Forcare Clinical Research Inc, Tampa, Florida

Hamilton Research LLC, Alpharetta, Georgia

Northshore Medical Group, Skokie, Illinois

Indiana Clinical Trial Center, Plainfield, Indiana

University of Iowa, Iowa City, Iowa

Equity Medical, Bowling Green, Kentucky

Tufts Medical Center, Boston, Massachusetts

Metro Boston Clinical Partners, Brighton, Massachusetts

The Derm Institute of West Michigan, Caledonia, Michigan

Henry Ford Hospital, Detroit, Michigan

Hamzavi Dermatology, Fort Gratiot, Michigan

Somerset Skin Centre, Troy, Michigan

Minnesota Clinical Study Center, New Brighton, Minnesota

Cleaver Dermatology, Kirksville, Missouri

MediSearch Clinical Trials, Saint Joseph, Missouri

Mount Sinai Doctors Dermatology, New York, New York

Sadick Research Group, New York, New York

Wilmington Dermatology Center, Wilmington, North Carolina

Optima Research, Boardman, Ohio

Apex Dermatology Mayfield Heights, Mayfield Heights, Ohio

Oregon Medical Research Center, Portland, Oregon

Oregon Dermatology and Research Center, Portland, Oregon

Clinical Research Philadelphia, Philadelphia, Pennsylvania

UPMC Department of Dermatology, Pittsburgh, Pennsylvania

Health Concepts, Rapid City, South Dakota

Advanced Research Experts PLLC, Nashville, Tennessee

Arlington Research Center, Inc., Arlington, Texas

Modern Research Associates PLLC, Dallas, Texas

Center for Clinical Studies, Houston, Texas

Progressive Clinical Research, San Antonio, Texas

Texas Dermatology and Laser Specialists, San Antonio, Texas

Center for Clinical Studies, Webster, Texas

Kalo Clinical Research, West Valley City, Utah

Frontier Derm Partners CRO, LLC, Mill Creek, Washington

Consultora Integral de Salud SRL, Barrio Gral Paz Cba Capital, Not set

Instituto Medico De Alta Complejidad (IMAC), Buenos Aires, Not set

Mindout Research, Buenos Aires, Not set

Instituto de Neumonologia y Dermatologia, Buenos Aires, Not set

Buenos Aires Skin, Caba, Not set

Investigaciones Medicas IMOBA SRL, Caba, Not set

CIPREC, Caba, Not set

Halitus Instituto Medico S.A. - Dermatologia y Estetica, Caba, Not set

Mautalen Salud e Investigacion, Caba, Not set

Hospital Italiano de Buenos Aires, Caba, Not set

Instituto De Especialidades De La Salud SRL, Rosario, Not set

MR Medicina Reumatologica, San Fernando, Not set

Instituto de Investigaciones Medicas Tucuman, Tucuman, Not set

Monash Medical Centre, Clayton, Not set

Cornerstone Dermatology, Coorparoo, Not set

Premier Specialists, Kogarah, Not set

The Alfred Hospital, Melbourne, Not set

Royal Melbourne Hospital, Melbourne, Not set

ISHI dermatology, Mitcham, Not set

Westmead Hospital, Westmead, Not set

Veracity Clinical Research, Woolloongabba, Not set

LKH Feldkirch, Feldkirch, Not set

Kepler Universitatsklinikum GmbH, Linz, Not set

Universtitatsklinikum St Polten, Sankt Polten, Not set

Allgemeines Krankenhaus der Stadt Wien, Wien, Not set

UZ Brussel, Brussel, Not set

AZ St. Lucas, Gent, Not set

Ghent University Hospital, Ghent, Not set

Universitair Ziekenhuis Leuven, Leuven, Not set

Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman, Liege, Not set

Dermatologie Maldegem, Maldegem, Not set

Skincare Studio Inc Dermatology Clinical Trials, St Johns, Newfoundland and Labrador

CCA Medical Research Corporation, Ajax, Ontario

SimcoDerm Medical and Surgical Dermatology Centre, Barrie, Ontario

Dermatrials Research, Hamilton, Ontario

Lovegrove Dermatology, London, Ontario

Lynderm Research Inc., Markham, Ontario

Alliance Clinical Trials, Waterloo, Ontario

Innovaderm Research Inc., Montreal, Quebec

The Centre de recherche Saint-Louis, Quebec, Not set

Aalborg Sygehus Syd, Aalborg, Not set

Aarhus University Hospital, Aarhus, Not set

Gentofte Hospital, Hellerup, Not set

Bispebjerg Hospital, Kobenhavn NV, Not set

Odense University Hospital, Odense, Not set

Sjællands University hospital, Roskilde, Not set

Klinikum Augsburg, Augsburg, Not set

Fachklinik Bad Bentheim, Bad Bentheim, Not set

ISA - Interdisciplinary Study Association GmbH, Berlin, Not set

Universitatsklinikum Bonn, Bonn, Not set

Studienzentrum an der Hase GbR, Bramsche, Not set

Rosenpark Research GmbH, Darmstadt, Not set

Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden, Dresden, Not set

Derma-Study-Center Friedrichshafen GmbH, Friedrichshafen, Not set

Universitaetsklinikum Schleswig Holstein Campus Kiel, Kiel, Not set

Studienzentrum Dr Schwarz Germany, Langenau, Not set

Dermatologie Mahlow, Mahlow, Not set

Gemeinschaftspraxis Dres. Quist, Mainz, Not set

Universitaetsklinikum Muenster, Muenster, Not set

Hautarztpraxis, Witten, Not set

Obudai Egeszsegugyi Centrum Kft, Budapest, Not set

Uno Medical Trials Ltd., Budapest, Not set

Derma-B Kft, Debrecen, Not set

Debreceni Egyetem Klinikai Kozpont, Debrecen, Not set

Gyongyosi Bugat Pal Korhaz, Gyongyos, Not set

Synexus Magyarorszag Kft, Gyula, Not set

Porcika Klinika - Vasarhelyi Sarkanyfu Kft., Hodmezovasarhely, Not set

Somogy Varmegyei Kaposi Mor Oktato Korhaz, Kaposvar, Not set

Bacs-kiskun Megyei Korhaz, Kecskemet, Not set

Allergo-Derm Bakos Kft., Szolnok, Not set

Medmare Egeszsegugyi Es Szolgaltato Bt., Veszprem, Not set

Osteo-Medic s.c A. Racewicz, J Supronik, Bialystok, Not set

Specderm Poznanska sp j, Bialystok, Not set

Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska, Elblag, Not set

Care Clinic Sp z o o, Katowice, Not set

Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna, Krakow, Not set

Dermed Centrum Medyczne Sp z o o, Lodz, Not set

Etyka Osrodek Badan Klinicznych Tomasz Pesta S K A, Olsztyn, Not set

SOLUMED Centrum Medyczne, Poznan, Not set

Velocity Skierniewice sp z o o, Skierniewice, Not set

Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej, Warszawa, Not set

Klinika Ambroziak Dermatologia, Warszawa, Not set

WroMedica, Wroclaw, Not set

Centrum Medyczne Oporow, Wroclaw, Not set

Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes, Braga, Not set

Unidade Local De Saude Da Regiao De Leiria Epe, Leiria, Not set

Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos, Lisboa, Not set

Hosp. Cuf Descobertas, Lisboa, Not set

Ulssa Hosp. Santo Antonio, Porto, Not set

Hosp. Gral. Univ. Dr. Balmis, Alicante, Not set

Hosp. Univ. de Cruces, Barakaldo, Not set

Hosp. Clinic de Barcelona, Barcelona, Not set

Hosp. Univ. San Cecilio, Granada, Not set

Grupo Dermatologico Y Estetico Pedro Jaen, Madrid, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. de Manises, Manises, Not set

Hosp. Clinico Univ. de Santiago, Santiago Compostela, Not set

Hosp. Virgen Macarena, Sevilla, Not set

Hosp. Ntra. Sra. de Valme, Sevilla, Not set

Hosp. Univ. I Politecni La Fe, Valencia, Not set

Hosp. de La Marina Baixa, Villajoyosa, Not set

Hosp. Clinico Univ. Lozano Blesa, Zaragoza, Not set

Hosp. Univ. Miguel Servet, Zaragoza, Not set

Dudley Group NHS Foundation Trust, Dudley, Not set

London North West University Healthcare NHS Trust, Harrow, Not set

The Queen Elizabeth Hospital NHS Foundation Trust, Kings Lynn, Not set

Guys and St Thomas NHS Foundation Trust, London, Not set

Royal Berkshire Hospital, Reading, Not set

Salford Royal Hospital, Salford, Not set

University Hospital Southampton, Southampton, Not set

Mid Yorkshire NHS Trust, Wakefield, Not set

Conditions: Plaque Psoriasis

Learn More ›

Clinical Performance of Three Daily Disposable Silicone Hydrogel Contact Lenses

NCT06778057

Recruiting

This is a subject-masked, randomized, prospective, bilateral, 3x3 crossover dispensing clinical investigation to assess the clinical performance of a new lens type comparison.

Gender:

ALL

Ages:

Between 18 years and 40 years

Trial Updated:

07/17/2025

Locations: The University of Manchester, Department of Optometry & Neuroscience, Manchester, Not set

Conditions: Visual Acuity

Learn More ›

PulseSelect™ PFA Global Registry

NCT06393920

Recruiting

The PulseSelect™ PFA Global Registry is a prospective, global, multi-center, observational post-approval study. Subjects will be treated with the PulseSelect™ PFA System and followed according to SOC.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/17/2025

Locations: Vancouver General Hospital, Vancouver, British Columbia +14 locations

Conditions: Atrial Fibrillation

Learn More ›

A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)

NCT06305767

Recruiting

Researchers are looking for new ways to treat people with high-risk muscle-invasive urothelial carcinoma (MIUC). Urothelial carcinoma is a type of bladder cancer that begins in cells that line the inside of the bladder and other parts of the urinary tract, such as part of the kidneys, ureters, and urethra. People with MIUC usually have chemotherapy before surgery, then surgery to remove the cancer. Chemotherapy is a type of medicine to destroy cancer cells or stop them from growing. After surger... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/16/2025

Locations: UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104), Los Angeles, California +73 locations

UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104), Los Angeles, California

AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlandoc ( Site 0102), Orlando, Florida

University of Chicago Medical Center ( Site 0109), Chicago, Illinois

University of Iowa ( Site 0110), Iowa City, Iowa

Icahn School of Medicine at Mount Sinai ( Site 0101), New York, New York

Duke Cancer Institute ( Site 0107), Durham, North Carolina

Cleveland Clinic Main ( Site 0100), Cleveland, Ohio

Fox Chase Cancer Center ( Site 0106), Philadelphia, Pennsylvania

UT Southwestern Medical Center ( Site 0103), Dallas, Texas

Houston Methodist Hospital-Department of Urology ( Site 0111), Houston, Texas

Macquarie University-MQ Health Clinical Trials Unit ( Site 1803), Macquarie University, New South Wales

Westmead Hospital ( Site 1802), Westmead, New South Wales

Mater Misericordiae Limited ( Site 1808), South Brisbane, Queensland

One Clinical Research ( Site 1807), Nedlands, Western Australia

BC Cancer Vancouver ( Site 0004), Vancouver, British Columbia

Princess Margaret Cancer Centre ( Site 0003), Toronto, Ontario

Centre Hospitalier de l'Université de Montréal ( Site 0005), Montréal, Quebec

Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0001), Quebec City, Quebec

Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0002), Sherbrooke, Quebec

CIDO SpA ( Site 1509), Temuco, Araucania

Bradfordhill-Clinical Area ( Site 1501), Recoleta, Santiago, Region M. De Santiago

FALP ( Site 1500), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 1503), Santiago, Region M. De Santiago

ONCOCENTRO APYS-ACEREY ( Site 1506), Viña del Mar, Valparaiso

Sociedad De Oncologia Y Hematologia Del Cesar-Oncology ( Site 1605), Valledupar, Cesar

Instituto Nacional De Cancerologia-Oncología Clínica ( Site 1606), Bogota, Cundinamarca

Clínica Universitaria Colombia ( Site 1600), Bogotá, Distrito Capital De Bogota

Fundacion Valle del Lili- CIC-Oncology CIC ( Site 1608), Cali, Valle Del Cauca

Oncopole Claudius Regaud ( Site 0302), Toulouse, Haute-Garonne

Gustave Roussy ( Site 0303), Villejuif, Ile-de-France

Institut de Cancérologie de l'Ouest ( Site 0300), ANGERS cedex 02, Maine-et-Loire

Hopital Claude Huriez - CHU de Lille ( Site 0301), Lille, Nord

Hôpital Saint-Louis ( Site 0304), Paris, Not set

klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0401), Munich, Bayern

Caritas-Krankenhaus St. Josef-Klinik fuer Urologie ( Site 0404), Regensburg, Bayern

Universitätsklinikum Halle-Universitätsklinik und Poliklinik für Urologie ( Site 0402), Halle, Sachsen-Anhalt

Universitaetsklinikum Carl Gustav Carus Dresden-Klinik und Poliklinik für Urologie ( Site 0405), Dresden, Sachsen

Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0400), Berlin, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 0504), Roma, Lazio

Ospedale San Martino-U.O. Oncologia Medica 1 ( Site 0500), Genova, Liguria

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0502), Milan, Lombardia

Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli-UOSC Oncologia ( Site 0503), Naples, Napoli

Ospedale San Raffaele-Oncologia Medica ( Site 0501), Milano, Not set

Korea University Anam Hospital ( Site 2002), Seoul, Not set

Seoul National University Hospital-Urology ( Site 2000), Seoul, Not set

Samsung Medical Center-Urology ( Site 2001), Seoul, Not set

Auckland City Hospital ( Site 1901), Auckland, Not set

IPOR Instituto Peruano de Oncología & Radioterapia ( Site 1702), Lima, Not set

Oncosalud ( Site 1701), Lima, Not set

Hospital Militar Central Luis Arias Schereiber ( Site 1700), Lima, Not set

Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 0801), Bydgoszcz, Kujawsko-pomorskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Moczowego ( Site 0800), Warszawa, Mazowieckie

Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zaklad Opieki Zdrowotnej ( Site 0806), Kielce, Swietokrzyskie

Clinical Research Center Spółka z ograniczoną odpowiedzialnością MEDIC-R Sp.k ( Site 0805), Poznan, Wielkopolskie

Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0802), Koszalin, Zachodniopomorskie

Hospital Germans Trias i Pujol-Instituto Catalán de Oncología de Badalona ( Site 1006), Badalona, Barcelona

Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1005), Madrid, Madrid, Comunidad De

HOSPITAL UNIVERSITARIO QUIRONSALUD MADRID-ONCOLOGIA MEDICA ( Site 1003), Pozuelo de Alarcon, Madrid

Hospital Universitari Vall d'Hebron-Oncology ( Site 1002), Barcelona, Not set

HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1001), Sevilla, Not set

Karolinska Universitetssjukhuset Solna ( Site 1101), Stockholm, Stockholms Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1102), Uppsala, Uppsala Lan

Hacettepe Universite Hastaneleri-oncology hospital ( Site 1200), Ankara, Not set

Memorial Ankara Hastanesi-Medical Oncology ( Site 1204), Ankara, Not set

Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1201), Ankara, Not set

Koc Universitesi Hastanesi ( Site 1206), Istanbul, Not set

T.C. Saglik Bakanligi Turkiye Kamu Hastaneleri Kurumu - Baki-Istanbul Bakirkoy Sadi Konuk Training ( Site 1205), Istanbul, Not set

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1202), Istanbul, Not set

Ege Universitesi Hastanesi-Medical Oncology ( Site 1203), Izmir, Not set

Torbay Hospital ( Site 1303), Torquay, Devon

Royal Free Hospital ( Site 1300), London, England

Gartnavel General Hospital-Clinical Trials Unit ( Site 1301), Glasgow, Glasgow City

St Bartholomew's Hospital-Centre for Experimental Cancer Medicine ( Site 1302), London, London, City Of

The Christie NHS Foundation Trust ( Site 1306), Manchester, Not set

Conditions: Bladder Cancer

Learn More ›

A Comparison of THD® Anopress With High Resolution Anorectal Manometry

NCT07083908

Recruiting

Currently, high resolution anorectal manometry (HDARM) is used as gold standard to measure anal sphincter pressures in women who have sustained a third or fourth degree perineal tears (obstetric anal sphincter injuries). This test is performed to help advise patients on future pregnancies or deliveries. However, HDRM catheters are very expensive and they also need to be performed in a dedicated procedure room. THD® Anopress in comparison is a lightweight, portable device which has a comparativel... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/16/2025

Locations: Kings College Hospital, London, Not set

Conditions: Obstetric Anal Sphincter Injury

Learn More ›

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

NCT04833894

Recruiting

The purpose of this trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG. Trial details include: * The maximum trial duration for each individual participant will be approximately 28 weeks * The treatment duration will be 8 weeks for the dose-confirmatory part (Part A) and 18 weeks for the treatment response-confirmatory part (Part B)

Gender:

ALL

Ages:

Between 2 years and 18 years

Trial Updated:

07/16/2025

Locations: Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois +23 locations

Ann and Robert H Lurie Children's Hospital of Chicago - Main Hospital, Chicago, Illinois

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

University of Virginia (UVA) Health - Developmental Pediatrics Clinic, Charlottesville, Virginia

Medizinische Universitat Wien, Wien, Not set

Universitair Ziekenhuis Antwerpen, Antwerpen, Not set

British Columbia Children's Hospital, Vancouver, Not set

AP-HM - Hopital de la Timone, Marseille, Not set

Assistance Publique Hopitaux de Paris (AP-HP) - Hopital Necker-Enfants Malades, Paris, Not set

Vian - M. Iashvili Children's Central Hospital, Tbilisi, Not set

Tbilisi State Medical University - Givi Zhvania Pediatric Academic Clinic, Tbilisi, Not set

Charite Universitaetsmedizin Berlin - Campus Virchow-Klinikum - Sozialpadiatrisches Zentrum, Berlin, Not set

Universitätsklinikum Essen, Essen, Not set

Azienda Ospedaliera Universitaria Policlinico Consorziale Di Bari, Bari, Not set

Azienda Ospedaliero Universitaria A. Meyer, Florence, Not set

Ospedale Giannina Gaslini, Genova, Not set

Leids Universitair Medisch Centrum, Leiden, Not set

Uniwersyteckie Centrum Kliniczne, Gdańsk, Woj. Pomorskie

Wielospecjalistyczna Poradnia Lekarska Synapsis, Katowice, Woj. Slaskie

Centralny Szpital Kliniczny - Uniwersyteckie Centrum Kliniczne WUM, Warszawa, Not set

Hospital Sant Joan de Deu, Esplugues De Llobregat, Not set

Hospital Universitari i Politecnic La Fe de Valencia, Valencia, Not set

Great Ormand Street Hospital for Children NHS Foundation Trust - Great Ormond Street Hospital, London, Not set

Manchester University NHS Foundation Trust - Royal Manchester Children's Hospital, Manchester, Not set

Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital Children's Hospital, Oxford, Not set

Conditions: Generalized Myasthenia Gravis

Learn More ›